

# Value IN HEALTH

VOLUME 18

NUMBER 2

MARCH/APRIL 2015

## TABLE OF CONTENTS

**COMMENTARY**

- 137 Potential Application of Machine Learning in Health Outcomes Research and Some Statistical Cautions**

William H. Crown

**EDITORIALS**

- 141 Clinical Trials Provide Essential Evidence, but Rarely Offer a Vehicle for Cost-Effectiveness Analysis**

Mark Sculpher

- 143 Dynamic Simulation in Health Care Comes of Age**

Mark S. Roberts

- 145 Merging Regulatory and Reimbursement Needs in Clinical Trial Design**

John R. Cook

**ISPOR TASK FORCE REPORTS**

- 147 Selecting a Dynamic Simulation Modeling Method for Health Care Delivery Research—Part 2: Report of the ISPOR Dynamic Simulation Modeling Emerging Good Practices Task Force**

Deborah A. Marshall, Lina Burgos-Liz, Maarten J. Ijzerman, William Crown, William V. Padula, Peter K. Wong, Kalyan S. Pasupathy, Mitchell K. Higashi, and Nathaniel D. Osgood, the ISPOR Emerging Good Practices Task Force

- 161 Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report**

Scott D. Ramsey, Richard J. Willke, Henry Glick, Shelby D. Reed, Federico Augustovski, Bengt Jonsson, Andrew Briggs, and Sean D. Sullivan

**ORIGINAL ARTICLES*****Economic Evaluation***

- 173 Economic Evaluation of Tocilizumab Monotherapy Compared to Adalimumab Monotherapy in the Treatment of Severe Active Rheumatoid Arthritis**

Josh J. Carlson, Sarika Ogale, Fred Dejonckheere, and Sean D. Sullivan

- 180 Strengthening Tuberculosis Control Overseas: Who Benefits?**

Hoa Thi Minh Nguyen, Roslyn I. Hickson, Tom Kompas, Geoffry N. Mercer, and Kamalini M. Lokuge

- 189 Comparing the Cost-Effectiveness of Rituximab Maintenance and Radioimmunotherapy Consolidation versus Observation Following First-Line Therapy in Patients with Follicular Lymphoma**

Qiushi Chen, Turgay Ayer, Loretta J. Nastoupil, Adam C. Rose, and Christopher R. Flowers

- 198 Effect of Adherence and Insulin Delivery System on Clinical and Economic Outcomes among Patients with Type 2 Diabetes Initiating Insulin Treatment**

Rajeev Ayyagari, Wenhui Wei, David Cheng, Chunshen Pan, James Signorovitch, and Eric Q. Wu

***Patient-Reported Outcomes***

- 206 Predictors of Self-Reported Adherence to Antihypertensive Medicines: A Multinational, Cross-Sectional Survey**

Valerie L. Morrison, Emily A.F. Holmes, Sahdia Parveen, Catrin O. Plumptre, Wendy Clyne, Sabina De Geest, Fabienne Dobbels, Bernard Vrijens, Przemyslaw Kardas, and Dyfrig A. Hughes

## TABLE OF CONTENTS - continued

### *Preference-Based Assessments*

#### **217 Learning and Satisficing: An Analysis of Sequence Effects in Health Valuation**

Benjamin M. Craig, Shannon K. Runge, Kim Rand-Hendriksen, Juan Manuel Ramos-Goñi, and Mark Oppe

#### **224 Public Preferences for Prioritizing Preventive and Curative Health Care Interventions: A Discrete Choice Experiment**

Jeroen Luyten, Roselinde Kessels, Peter Goos, and Philippe Beutels

### *Comparative Effectiveness Research/Health Technology Assessment (HTA)*

#### **234 Critical Appraisal of Network Meta-Analyses Evaluating the Efficacy and Safety of New Oral Anticoagulants in Atrial Fibrillation Stroke Prevention Trials**

Shannon Cope, Andreas Clemens, Florence Hammès, Herbert Noack, and Jeroen P. Jansen

#### **250 A Unified Framework for Classification of Methods for Benefit-Risk Assessment**

Mehdi Najafzadeh, Sebastian Schneeweiss, Niteesh Choudhry, Katsiaryna Bykov, Kristijan H. Kahler, Diane P. Martin, and Joshua J. Gagne

#### **260 Application of Multicategory Exposure Marginal Structural Models to Investigate the Association between Long-Acting Beta-Agonists and Prescribing of Oral Corticosteroids for Asthma Exacerbations in the Clinical Practice Research Datalink**

Ayad K. Ali, Abraham G. Hartzema, Almut G. Winterstein, Richard Segal, Xiaomin Lu, and Leslie Hendeles

#### **271 The Changing Face of the Cost-Utility Literature, 1990–2012**

Peter J. Neumann, Teja Thorat, Jennifer Shi, Cayla J. Saret, and Joshua T. Cohen

### *Health Policy Analysis*

#### **278 Fairness versus Efficiency of Vaccine Allocation Strategies**

Ming Yi and Achla Marathe

#### **284 Which Factors Enhance Positive Drug Reimbursement Recommendation in Scotland? A Retrospective Analysis 2006–2013**

Mata Charokopou, Istvan M. Majer, Johan de Raad, Stefan Broekhuizen, Maarten Postma, and Bart Heeg

### **METHODOLOGICAL ARTICLES**

#### **292 Implications of the Minimal Clinically Important Difference for Health-Related Quality-of-Life Outcomes: A Comparison of Sample Size Requirements for an Incontinence Treatment Trial**

Alex S. Halme, Xavier Fritel, Andrea Benedetti, Ken Eng, and Cara Tannenbaum

#### **299 Mapping the Clinical Chronic Obstructive Pulmonary Disease Questionnaire onto Generic Preference-Based EQ-5D Values**

Melinde R.S. Boland, Job F.M. van Boven, Janwillem W.H. Kocks, Thys van der Molen, Lucas M. Goossens, Niels H. Chavannes, and Maureen P.M.H. Rutten-van Mölken

### **SYSTEMATIC REVIEWS**

#### **308 Cost-Utility Analyses in Diabetes: A Systematic Review and Implications from Real-World Evidence**

Yue Zhong, Pei-Jung Lin, Joshua T. Cohen, Aaron N. Winn, and Peter J. Neumann

#### **315 A Systematic Review of Generic Multidimensional Patient-Reported Outcome Measures for Children, Part I: Descriptive Characteristics**

Astrid Janssens, Jo Thompson Coon, Morwenna Rogers, Karen Allen, Colin Green, Crispin Jenkinson, Alan Tennant, Stuart Logan, and Christopher Morris

## TABLE OF CONTENTS - continued

**334 A Systematic Review of Generic Multidimensional Patient-Reported Outcome Measures for Children, Part II: Evaluation of Psychometric Performance of English-Language Versions in a General Population**

Astrid Janssens, Morwenna Rogers, Jo Thompson-Coon, Karen Allen, Colin Green, Crispin Jenkinson, Alan Tennant, Stuart Logan, and Christopher Morris

### **POLICY PERSPECTIVES**

**346 Need for Multicriteria Evaluation of Generic Drug Policies**

Zoltán Kaló, Anke-Peggy Holtorf, Rafael Alfonso-Cristancho, Jie Shen, Tamás Ágh, András Inotai, and Diana Brixner

### **LETTER TO THE EDITOR**

**352 Do the Current Performance-Based Schemes in Italy Really Work? “Success Fee”: A Novel Measure for Cost-Containment of Drug Expenditure**

Livio Garattini, A. Curto and K. van de Vooren

**353 Errata**

**I Instructions for Authors**